Health Care Costs
In a systematic review, researchers explored the financial burden of treating grade 3 to 4 adverse events associated with melanoma and its treatment.
Use of opioids to manage cancer-related pain may have adverse effects of its own that can have a significant impact on healthcare use among patients with cancer.
Survey responses revealed that clinicians and patients do not agree on whether discussions regarding the impact of treatment on employment and/or financial status occur or are helpful.
This overview provides a snapshot of the shift in cancer care costs and age of patients, reviewing the 4 most commonly diagnosed cancers.
Cost of cancer care is more than co-pays for medications and treatment. Cancer can affect a patient's ability to work compounding the financial costs of their care, as described in this presentation at the 2018 ONA Navigation Summit.
An intervention utilizing lay health workers supervised by NPs lowered health care costs and improved patient satisfaction.
Survey results presented at the 2018 ASCO Annual Meeting demonstrated the effects of financial toxicity on patients with early stage breast cancer.
1. In this meta-analysis of available studies, early palliative care consultation (PCC) for patients admitted to hospital with serious illness was associated with a reduction in direct hospital costs for that admission. 2. The reduction in direct hospital costs was greater for those patients with a cancer diagnosis and for those with 4 or more 
A meta-analysis shows that earlier initiation of palliative care can effectively change patterns of care for patients with higher illness burden.
In a study that evaluated outcomes for younger, working age women with breast cancer, researchers identified differences in cancer-related financial adverse events in black women vs white women.
In a quasi-experimental pre-post study, researchers demonstrate the efficacy of the SEE-ACBT rehabilitation method on health-related and cost outcomes in patients with NSCLC who underwent curative lung resection.
In the 2010 to 2016 period, the proportion of survivors reporting delayed medical care decreased yearly.
At $225 million per system, the precision of proton beam radiotherapy is not necessarily overshadowing its high costs. Yet ongoing studies seek to determine how this technology fits into current treatment regimens for prostate, breast, and other cancers.
The Affordable Care Act was linked to reduced cost burdens for middle to low-income households, study data indicate.
Researchers report on their findings of a retrospective study that compared pomalidomide plus dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Research presented at the 2018 Gastrointestinal Cancers Symposium described benefits seen with RAMIE vs chemotherapy or chemoradiotherapy plus OTE for esophageal cancer.
Multimodal screening is more expensive, but reduces ovarian cancer mortality, researchers found.
Recent study findings investigated the economic burden of patients with relapsed Ph-negative ALL, and the adverse events of special interest that are most likely to have the greatest impact. These findings were presented at ASH 2017.
A single-center analysis demonstrates likelihood that mastalgia indicates presence of breast cancer and extensiveness of common work-up for the complaint. These findings were presented at SABCS 2017.
A cross-sectional survey revealed the impact of symptoms and economic burden on quality of life for survivors of gastrointestinal cancer.
Investigators sought to determine clinical and cost effectiveness of additional colonoscopy screening in patients undergoing FIT screening for colorectal cancer.
Development of carcinoid syndrome has a profound effect on cost of care for patients with neuroendocrine tumors (NETs).
Total revenue from sales of 10 drugs was 67.0 billion, with total RD spending of 7.2 billion, researchers found.
Cancer treatment is far costlier than expected, even for patients with cancer who have health insurance coverage, with being underinsured causing in the most distress for patients.
Roughly half of older Americans experiencing difficulty paying for needed drugs did not talk to their physicians about the issue, poll shows.
Research on the effects of research demonstrated that oncology-related clinical trials provide measurable benefits in terms
Doses May Be Adjusted for Treating NSCLC Patients
[Cancer Management and Research] This research examines the pros and cons of the Affordable Care Act enactment and the possible beneficial role biosimilars may play in this environment.
Risk of nonadherence was lower for survivors reporting a usual source of care than those without
More public tolerance for health care inequalities has been observed in the United States than other countries.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|